<DOC>
	<DOCNO>NCT02483767</DOCNO>
	<brief_summary>The study prospective randomize control clinical trial sponsor researcher . The purpose study determine effectiveness Gonadotropin-Releasing hormone agonist ovarian function premenopausal breast cancer patient chemotherapy . The premenopausal breast cancer patient randomly ( 1:1 ) enrol receive standard chemotherapy GnRH agonist goserelin ( goserelin group ) standard chemotherapy without goserelin ( chemotherapy alone group ) . All patient stratify accord age ( &lt; 35years vs.36-44years ) , hormone receptor status ( HR+ ER+ vs.HR- ER- ) , chemotherapy regimen ( 3-4 cycle vs.6-8 cycle , cyclophosphamide-based vs.noncyclophosphamide ) .The follow-up time least 2years . The ovarian failure , follicle-stimulating hormone , estradiol anti-Mullerian hormone , pregnancy outcomes disease-free overall survival compare two group evaluate effectiveness protect ovarian failure .</brief_summary>
	<brief_title>Gonadotropin-Releasing Hormone Agonist Preservation Ovarian Function During Chemotherapy Premenopausal Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>The patient sign write informed consent . Histologically proven stage I , II , III breast cancer Must candidate adjuvant neoadjuvant chemotherapy , Must premenopausal . Trastuzumab permit patient human epidermal growth factor receptor 2 ( HER2 ) overexpressing tumor . The patient previous chemotherapy ; Evidence distant metastasis ; Other malignancy previous 5 year . The patient use GnRHa , progesterone , stimulate ovulation drug , oral contraceptive , aromatase inhibitor , intrauterine device hormone , subcutaneous preparation contraceptive drug hormone drug instrument 3 month precede start chemotherapy . Pregnancy lactation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Premenopausal Breast Cancer</keyword>
	<keyword>Preservation Ovarian Function</keyword>
	<keyword>Gonadotropin-Releasing Hormone Agonist</keyword>
</DOC>